17:54 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer...
23:34 , Jan 25, 2018 |  BC Innovations  |  Targets & Mechanisms

Unexpected combinations

Two studies are prompting a rethink of how combination therapies target cancer at both the level of individual cells, and across a patient population. The papers are pushing drug developers to parse data from preclinical...
16:03 , Jan 15, 2018 |  BC Extra  |  Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

In a study published in...
20:23 , May 26, 2017 |  BC Week In Review  |  Company News

BioAtla, Beijing Sinobioway expand CAB deal

BioAtla LLC (San Diego, Calif.) and Beijing Sinobioway Group Ltd. (Beijing, China) added five products from BioAtla's Conditionally Active Biologic (CAB) platform to a 2015 deal granting Sinobioway exclusive rights to develop and commercialize similar...
20:46 , Dec 15, 2016 |  BC Innovations  |  Targets & Mechanisms

Keeping the Gas off AXL

With its development of an AXL decoy able to trap and sequester the native receptor’s ligand with femtomolar affinity, Aravive Biologics Inc. believes it has a biologic that can bypass the potency and selectivity issues...
23:12 , Nov 2, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Patient sample, cell culture and mouse studies suggest inhibiting AXL could help treat ovarian cancer. In patients, high tumor expression of AXL correlated with poor overall survival. In two human ovarian cancer...